logo
Plus   Neg
Share
Email

Tandem Diabetes Care (TNDM) Is Up After FDA Approval

Tandem Diabetes Care (TNDM) announced after the bell Thursday that it received approval fro the FDA for the t:slim X2 Insulin Pump with Basal-IQ technology. The stock is now up 0.89 on 40K shares.

Tandem Diabetes Care traded in a range for the bulk of Thursday's session and closed down by 0.37 at $20.31. The stock pulled back slightly from the highs of the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT